| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Alexandru Eniu | |
| Jose Bines | |||
| P2860 | cites work | Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 |
| Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility | Q28239961 | ||
| Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers | Q28375856 | ||
| Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer | Q33996115 | ||
| Effect of screening and adjuvant therapy on mortality from breast cancer | Q34463105 | ||
| Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer | Q34496969 | ||
| The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen | Q34653100 | ||
| Targeted therapy: wave of the future. | Q36065510 | ||
| Racial and ethnic disparities in breast cancer mortality: are we doing enough to address the root causes? | Q36472202 | ||
| Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation | Q40342717 | ||
| Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. | Q44362100 | ||
| Adjuvant docetaxel for node-positive breast cancer | Q46522790 | ||
| What is the most cost-effective population-based cancer screening program for Chinese women? | Q51765996 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. | Q55033930 | ||
| Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial | Q66829419 | ||
| Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels | Q77683633 | ||
| Cost effectiveness in context | Q79794460 | ||
| Closing the affordability gap for drugs in low-income countries | Q79836465 | ||
| Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study | Q80466194 | ||
| The value meal: how to save $1,700 per month or more on lapatinib | Q80628256 | ||
| What is targeted therapy? | Q81498284 | ||
| P433 | issue | 8 Suppl | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | 2353-2358 | |
| P577 | publication date | 2008-10-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Effective but cost-prohibitive drugs in breast cancer treatment: a clinician's perspective | |
| P478 | volume | 113 |
| Q56690209 | Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial† |
| Q37989744 | Breast cancer in Brazil: present status and future goals |
| Q38066589 | Challenges in the management of breast cancer in low- and middle-income countries |
| Q37016004 | Defining a global research agenda for breast cancer |
| Q35611036 | Endpoints in advanced breast cancer: methodological aspects & clinical implications |
| Q33393452 | Gemcitabine and cisplatin salvage regimen in heavily pretreated metastatic breast cancer: a Brazilian experience |
| Q51948740 | Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. |
| Q30235988 | Improving access to high-cost cancer drugs in Latin America: Much to be done |
| Q27027277 | Preventing breast cancer in LMICs via screening and/or early detection: The real and the surreal |
| Q34423504 | The emerging breast cancer epidemic: early diagnosis and treatment. |
Search more.